Precision Biosciences (DTIL) Operating Income (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Operating Income of -$9.1 million for Q1 2026, up 58.96% year-over-year from -$5.7 million in Q1 2025, and down 172.55% quarter-over-quarter from $12.5 million in Q4 2025.
Precision Biosciences (DTIL) Operating Income (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Operating Income for 9 consecutive years, with -$9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 58.96% year-over-year to -$9.1 million; the TTM figure through Mar 2026 stood at -$39.1 million (up 11.29% YoY), while the FY2025 annual figure was -$52.1 million, down 99.33% from the prior year.
- Operating Income eased to -$9.1 million in Q1 2026 per DTIL's latest filing, from $12.5 million in the prior quarter.
- Across five years, Operating Income topped out at $24.1 million in Q2 2024 and bottomed at -$29.6 million in Q2 2022.
- Historically, Operating Income has averaged -$12.6 million across 5 years, with a median of -$14.7 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Income surged 871.68% — and 2025, when it plunged 428.11%.
- Precision Biosciences' Operating Income stood at -$12.1 million in 2022, then slipped by 22.97% to -$14.9 million in 2023, then slumped by 66.86% to -$24.8 million in 2024, then jumped by 150.34% to $12.5 million in 2025, then plunged by 172.55% to -$9.1 million in 2026.
- Business Quant data shows DTIL's Operating Income at -$9.1 million in Q1 2026, $12.5 million in Q4 2025, and -$20.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -19.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.16 Mn |
| Mar 31, 2026 | -9.08 Mn |
| Dec 31, 2025 | 12.51 Mn |
| Sep 30, 2025 | -20.67 Mn |
| Jun 30, 2025 | -21.88 Mn |
| Mar 31, 2025 | -22.11 Mn |
| Dec 31, 2024 | -24.85 Mn |
| Sep 30, 2024 | -21.28 Mn |
| Jun 30, 2024 | 24.15 Mn |
| Mar 31, 2024 | -4.19 Mn |
| Dec 31, 2023 | -14.89 Mn |
| Sep 30, 2023 | -12.36 Mn |
| Jun 30, 2023 | -3.13 Mn |
| Mar 31, 2023 | -13.35 Mn |
| Dec 31, 2022 | -12.11 Mn |
| Sep 30, 2022 | -14.68 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Mar 31, 2022 | -27.34 Mn |
| Dec 31, 2021 | -30.72 Mn |
| Sep 30, 2021 | -11.54 Mn |